A Biotinylated cpFIT-PNA Platform for the Facile Detection of Drug Resistance to Artemisinin in .

The evolution of drug resistance to many antimalarial drugs in the lethal strain of malaria () has been a great concern over the past 50 years. Among these drugs, artemisinin has become less effective for treating malaria. Indeed, several variants have become resistant to this drug, as elucidated by specific mutations in the pfK13 gene.

Correction: Cyclopentane FIT-PNAs: bright RNA sensors.

Correction for 'Cyclopentane FIT-PNAs: bright RNA sensors' by Odelia Tepper , , 2021, , 540-543, https://doi.org/10.1039/D0CC07400D.

FIT-PNAs as RNA-Sensing Probes for Drug-Resistant .

Detecting RNA at single-nucleotide resolution is a formidable task. is the deadliest form of malaria in humans and has shown to gain resistance to essentially all antimalarial drugs including artemisinin and chloroquine. Some of these drug resistances are associated with single-nucleotide polymorphisms (SNPs).

Cyclopentane FIT-PNAs: bright RNA sensors.

Cyclopentane modified FIT-PNA (cpFIT-PNA) probes are reported as highly emissive RNA sensors with the highest reported brightness for FIT-PNAs. Compared to FIT-PNAs, cpFIT-PNAs have improved mismatch discrimination for several pyrimidine-pyrimidine single nucleotide variants (SNVs).

Red-emitting FIT-PNAs: "On site" detection of RNA biomarkers in fresh human cancer tissues.

To date, there are limited approaches for the direct and rapid visualization (on site) of tumor tissues for pathological assessment and for aiding cytoreductive surgery. Herein, we have designed FIT-PNAs (forced-intercalation-peptide nucleic acids) to detect two RNA cancer biomarkers. Firstly, a lncRNA (long noncoding RNA) termed CCAT1, has been shown as an oncogenic lncRNA over-expressed in a variety of cancers.